Not yet filed. No Q3 2026 Form 13F from Hillman Capital Management has been detected on SEC EDGAR yet. The deadline for the quarter ended Sep 30, 2026 is Monday, Nov 16, 2026.
From the fund's 2026 Q2 Form 13F (filed Aug 14, 2026) — the latest quarter fully processed on this site.
| Stock | Shares | Portfolio weight |
|---|---|---|
| CVS · CVS HEALTH Corp | 55,475 | 4.15% |
| BIIB · BIOGEN INC. | 23,993 | 3.75% |
| DD · DuPont de Nemours, Inc. | 37,745 | 3.71% |
| WBD · Warner Bros. Discovery, Inc. | 189,986 | 3.67% |
| BAX · BAXTER INTERNATIONAL INC | 236,032 | 3.64% |
| IFF · INTERNATIONAL FLAVORS & FRAGRANCES INC | 62,875 | 3.61% |
| GSK · GSK plc | 92,383 | 3.51% |
| KMX · CARMAX INC | 91,385 | 3.50% |
| BA · BOEING CO | 21,574 | 3.38% |
| ZBH · ZIMMER BIOMET HOLDINGS, INC. | 53,943 | 3.36% |
Largest increase 2026 Q1 → 2026 Q2: MDT (+55.6% of shares). New position in 2026 Q2: DD (3.71% of the portfolio). Largest trim 2026 Q1 → 2026 Q2: TROW (-86.1% of shares). Exited in 2026 Q2: DD, GE.
Full record: Hillman Capital Management fund page · manager profile & 13F-clone record · Q3 2026 season tracker.
Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.